Welcome to our dedicated page for Stagezero Life news (Ticker: SZLSF), a resource for investors and traders seeking the latest updates and insights on Stagezero Life stock.
Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Stagezero Life's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.
Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Stagezero Life's position in the market.
StageZero Life Sciences, an integrated healthcare company specializing in mRNA gene expression multi-cancer diagnostics, announced updates on its 2023 financial filings under a Failure to File Cease Trade Order (FFCTO). The company had previously delayed filing due to insufficient funds to pay auditors. The Ontario Securities Commission granted StageZero until July 8, 2024, to file its year-end financials for automatic revocation of the FFCTO. Although the audit and associated documents, including MD&A and AIF, are nearly complete, final payment to auditors is still pending. The company is also compliant with its Q1 2024 financials. The FFCTO bans trading of StageZero's securities in Canada until the filing is completed and the FFCTO is revoked.
StageZero Life Sciences has provided an update on the filing of its full-year 2023 financials amid a Failure to File Cease Trade Order (FFCTO) imposed by the Ontario Securities Commission (OSC). The company cited financial constraints as a reason for the delayed audit in April. With the OSC's deadline fast approaching on July 8, 2024, StageZero has nearly completed the audit and is in the process of settling auditor fees. The FFCTO restricts any trading of the company's securities in Canada until the financial documents are filed and the order is revoked.
StageZero Life Sciences announced that it remains under a Failure to File Cease Trade Order (FFCTO) due to a delay in filing its 2023 year-end financials. The company cited insufficient financial resources to pay auditors as the cause of the delay. The Ontario Securities Commission has granted StageZero 90 days to rectify the situation, giving them a deadline of July 3, 2024. Despite efforts to file ahead of the deadline, StageZero will not meet the originally referenced May 31, 2024, filing date. The FFCTO prohibits any trading of the company's securities in Canada until the filings are completed and the order is revoked. StageZero confirms no other undisclosed material information about its affairs.
StageZero Life Sciences (TSX:SZLS) announced its Q1 2024 financial results and provided an operational update. The company reported revenue of $0.523 million for cancer testing and treatment, a decrease from $0.778 million in Q1 2023. Net loss reduced to $0.386 million from $1.812 million in the same period last year. Key developments include advanced discussions with multiple partners in the US and Canada, reorganization of the Richmond lab, and formalized business development in Europe. Upcoming catalysts for 2024 include new partnerships focused on Aristotle, Care Oncology US expansion, and multiple cancer studies. Gross profit was $0.302 million with a gross margin of 58%.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.